Strategic Intelligence for Tomorrow

  1. Home
  2. Reports Store
  3. Medical Devices
Market Analysis & Forecast

Point-of-Care Diagnostics Market

Report Code
CM-MD-P1-1003
Base Year
2025
Study Period
2021–2025 · 2026–2035
Geographic Scope
Global
Pages
180-220
Format
PPT / WORD / EXCEL / PDF
Published
October 2026
Delivery
48 hours
Back toHealthcare Reports

Customise your request

Need this report to answer something it does not cover? Tell us the decision you are facing and we will scope the work — or point you to a study that already answers it.

info@cortexmeridian.com+971 56 483 5090

Report Scope

Report ID / SKUCM-MD-0003
Report CodeCM-MD-P1-1003
Report TypeMarket Analysis & Forecast
Base Year2025
Historical Period2021–2025
Forecast Period2026–2035
Geographic ScopeGlobal
Global CoverageYes
Regions CoveredNorth America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Countries CoveredUS; Canada; Mexico; UK; Germany; France; Italy; Spain; Netherlands; Switzerland; China; India; Japan; South Korea; Australia; Brazil; Argentina; Saudi Arabia; UAE; South Africa (20 countries)
Market Size UnitUSD Billion
Volume UnitTests / Cartridges / Analyzers
Report FormatPPT / WORD / EXCEL / PDF
Page Count180-220
Delivery Timeline48 hours
Sample AvailableYes
Author / AnalystCortex Meridian Medical Devices Analyst Team
Publish DateOctober 2026
Last Updated2026-10-06

Market Overview & Definition

Market Overview & Definition

The Point-of-Care Diagnostics market is estimated by Cortex Meridian Research at USD 21.7 billion in 2025 and is projected to reach approximately USD 32.4 billion by 2035, reflecting a CAGR of 4.1%. The market is being reshaped by the economic value of faster decision-making rather than simply by test decentralization. In emergency, urgent-care, pharmacy and home settings, a test that avoids laboratory delay can reduce repeat visits, shorten time to treatment and improve patient routing. This is creating room for higher-value cartridge-based molecular systems alongside traditional low-cost rapid tests.

The strongest growth opportunities are in settings where speed and clinical sensitivity both matter. Molecular point-of-care testing, cardiac markers, coagulation and blood-gas analysis fit this profile particularly well. By contrast, commoditized lateral-flow categories remain highly price sensitive and face strong competition from regional and private-label suppliers.

Roche’s continued expansion of the cobas liat menu and Cepheid’s next-generation GeneXpert strategy show that major diagnostics companies view decentralized molecular testing as a long-term platform opportunity. Their advantage is not just analytical performance, but the ability to build recurring cartridge revenue around installed systems. The market is therefore likely to shift progressively toward connected, menu-rich platforms that can serve multiple clinical pathways rather than single-test devices.

Report Description

The Point-of-Care Diagnostics Market covers revenue generated from the defined medical-device products, related consumables and software/services where directly attached to the device workflow. The report excludes unrelated pharmaceuticals and stand-alone healthcare services. The scope is designed for manufacturers, suppliers, distributors, hospitals, diagnostic providers, investors and strategy teams evaluating demand, technology shifts, pricing and competitive opportunity.

Overall Market Dynamics

Drivers

Need for rapid clinical decisions, decentralization of care, home testing, emergency/ambulatory workflows and improved connectivity.

Restraints / Risks

Variable reimbursement, quality-control requirements outside central labs, operator training and price competition in rapid tests.

Opportunities

POC molecular testing, telehealth-enabled diagnostics, multiplex respiratory panels, home chronic-disease monitoring and emerging-market penetration.

Strategic themes

AI/connectivity, workflow efficiency, reimbursement, regulatory approvals, recurring consumables/service revenue, and regional access expansion.

Segmentation & Scope

Segmentation & Scope

By product: infectious disease, glucose, cardiac markers, blood gas/electrolytes, coagulation, pregnancy/fertility, urinalysis; by platform: lateral flow, cartridge, biosensor, molecular; by setting: hospitals, clinics, home, pharmacies, assisted living; by geography.

Regional & Country Outlook

Regional & Country Outlook

COUNTRY CHAPTER COVERAGE 1. US: POC market size; CLIA-waived testing; urgent care/pharmacy/home testing; reimbursement; molecular POC; Abbott/Roche/Cepheid competition. 2. Canada: decentralized testing; rural access; hospital POC; reimbursement; infectious disease and glucose testing. 3. UK: NHS near-patient testing; emergency/primary care use; POC governance; reimbursement; molecular POC. 4. Germany: hospital and physician-office testing; reimbursement; blood gas and cardiac marker use; molecular POC. 5. France: hospital POC; pharmacy/home testing; infectious disease; reimbursement; procurement. 6. Italy: hospital and emergency POC; regional adoption; glucose/blood gas; procurement. 7. Spain: primary care and hospital POC; infectious disease; reimbursement; decentralized workflows. 8. Netherlands: connected POC; primary care; anticoagulation and infectious disease testing; digital integration. 9. Switzerland: premium POC systems; hospital/clinic adoption; molecular and cardiac testing. 10. China: hospital POC expansion; domestic suppliers; infectious disease; glucose; pricing and procurement. 11. India: low-cost rapid tests; glucose; cardiac markers; infectious disease; rural and pharmacy channels. 12. Japan: hospital POC; aging-related testing; compact analyzers; reimbursement; quality standards. 13. South Korea: hospital and clinic POC; digital connectivity; molecular and cardiac testing. 14. Australia: rural/remote POC; primary care; infectious disease; reimbursement; indigenous health access. 15. Brazil: rapid testing; emergency care; public/private adoption; infectious disease; distributor economics. 16. Argentina: hospital POC; rapid tests; import dependence; pricing and access. 17. Saudi Arabia: hospital modernization; emergency POC; diabetes testing; tenders; localization. 18. UAE: private hospital POC; premium molecular systems; emergency and outpatient adoption. 19. South Africa: HIV/TB and infectious disease POC; rural access; public procurement; glucose testing.

Competitive Landscape & Companies Covered

Abbott; Roche; Danaher; Siemens Healthineers; BD; bioMérieux; QIAGEN; QuidelOrtho; Nova Biomedical; Werfen

Pricing & Ecosystem

Pricing, Cost & Revenue Intelligence

Pricing intelligence benchmarks capital-system ASPs, disposable/consumable pricing, procedure-linked device pricing, service contracts, software subscriptions and regional tender dynamics where applicable. The model distinguishes capital equipment from recurring revenue and evaluates discounting, bundling, distributor margins, reimbursement sensitivity and premium technology price realization.

Value Chain & Ecosystem Analysis

The ecosystem maps component and sensor suppliers, materials vendors, device OEMs, software/AI partners, contract manufacturers, sterilization and packaging providers, distributors, hospitals/diagnostic laboratories/ASCs, clinicians, payers and regulators. The analysis identifies control points in the value chain, recurring-revenue pools, channel dependencies and partnership opportunities.

Opportunity & White-Space Analysis

A weighted opportunity model scores product segments, technologies, countries, end users and accounts using growth, market size, clinical adoption, reimbursement, competitive intensity, regulatory accessibility and margin potential. Priority white spaces include POC molecular testing, telehealth-enabled diagnostics, multiplex respiratory panels, home chronic-disease monitoring and emerging-market penetration.

Executive Summary

Cortex Meridian Research estimates the Point-of-Care Diagnostics market at USD 21.7 billion in 2025, rising to about USD 32.4 billion by 2035 at a CAGR of 4.1%. Growth is driven by the clinical and economic benefit of shortening the diagnostic cycle, particularly in emergency care, urgent care, pharmacies and home settings.

The most attractive opportunity is not generic rapid testing but higher-value decentralized platforms that combine speed with laboratory-grade sensitivity. Roche’s cobas liat expansion and Cepheid’s GeneXpert roadmap illustrate how the market is moving toward recurring cartridge-based business models. Vendors that can broaden menus, integrate connectivity and support decentralized quality control are likely to capture disproportionate value, while basic rapid-test categories will remain exposed to pricing pressure.

Key Takeaways

  • 2025 Cortex normalized estimate: USD 21.7 billion
  • 2035 normalized outlook: USD 32.4 billion
  • Normalized 2025–2035 CAGR: 4.1%
  • Key growth drivers: Need for rapid clinical decisions, decentralization of care, home testing, emergency/ambulatory workflows and improved connectivity.
  • Priority opportunity areas: POC molecular testing, telehealth-enabled diagnostics, multiplex respiratory panels, home chronic-disease monitoring and emerging-market penetration.
  • Primary competitive set: Abbott; Roche; Danaher; Siemens Healthineers; BD; bioMérieux; QIAGEN; QuidelOrtho; Nova Biomedical; Werfen

Table of Contents

1.EXECUTIVE SUMMARY
1.1Point-of-Care Diagnostics Market snapshot
1.22025 market size and 2035 outlook
1.3Key growth opportunities
1.4Major risks and assumptions
2.MARKET DEFINITION & SCOPE
2.1Definition
2.2Inclusion/exclusion criteria
2.3Value-chain boundary
2.4Market-sizing logic
3.MARKET DYNAMICS
3.1Drivers
3.2Restraints
3.3Opportunities
3.4Technology trends
3.5Regulatory and reimbursement impact
4.MARKET SEGMENTATION & FORECAST
4.1By product/device type
4.2By technology
4.3By application/procedure
4.4By end user
4.5By geography
5.PRICING, PROCEDURE & REVENUE INTELLIGENCE
5.1ASP ranges
5.2Procedure/test utilization
5.3Capital vs recurring revenue
5.4Service/consumable economics
6.REGIONAL & COUNTRY ANALYSIS
6.1North America
6.2Europe
6.3Asia Pacific
6.4Latin America
6.5Middle East & Africa
7.COMPETITIVE LANDSCAPE
7.1Market structure
7.2Product benchmark
7.3Technology benchmark
7.4Regulatory approvals
7.5Partnerships and M&A
7.6Company profiles
8.OPPORTUNITY & COMMERCIAL INTELLIGENCE
8.1Opportunity heat map
8.2High-growth segments
8.3White-space opportunities
8.4Target customer groups
8.5Go-to-market implications
9.METHODOLOGY
9.1Primary research
9.2Secondary research
9.3Market sizing
9.4Forecasting and validation
10.APPENDIX
6.REGIONAL & COUNTRY MARKET CHAPTERS
6.1US market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.2Canada market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.3UK market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.4Germany market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.5France market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.6Italy market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.7Spain market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.8Netherlands market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.9Switzerland market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.10China market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.11India market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.12Japan market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.13South Korea market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.14Australia market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.15Brazil market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.16Argentina market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.17Saudi Arabia market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.18UAE market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities
6.19South Africa market size, forecast, product/technology mix, demand drivers, reimbursement/procurement, competition and opportunities

List of Tables

  1. Global market value, 2021–2035
  2. Market by product/device type
  3. Market by technology
  4. Market by application/procedure
  5. Market by end user
  6. Market by region
  7. Country market sizing
  8. Installed base/procedure/test indicators
  9. ASP/pricing benchmark
  10. Company/product benchmark
  11. Opportunity attractiveness scoring

List of Figures

  1. Market size and CAGR outlook
  2. Segment attractiveness matrix
  3. Technology adoption curve
  4. Regional opportunity heat map
  5. Competitive positioning matrix
  6. Value-chain ecosystem map
  7. Pricing/revenue model
  8. Opportunity prioritization matrix

Research Methodology

Methodology

Cortex Meridian Research applies a triangulated market-sizing framework combining company disclosures, regulatory databases, procedure/test volumes, installed-base indicators, shipment and utilization data, hospital and laboratory purchasing patterns, reimbursement signals, product approvals, and primary research. Public market benchmarks are used only as external calibration points; Cortex values are normalized to the defined scope and forecast period. Forecasts consider technology adoption, procedure/test growth, replacement cycles, pricing, reimbursement, regulatory changes, and regional healthcare investment.

Data Sources & Validation

Company annual reports and investor materials; FDA, EMA and other regulatory databases; WHO and national health agencies; peer-reviewed clinical literature; procurement and reimbursement sources; hospital/laboratory statistics; trade and shipment indicators; company product portfolios; primary interviews; and public market benchmarks used for calibration.

FAQ — Buyer Questions

Q: What is the 2025 global Point-of-Care Diagnostics market size? A: Cortex Meridian Research estimates it at approximately USD 21.7 billion.

Q: What is the 2035 market outlook? A: The normalized outlook is approximately USD 32.4 billion, based on a 4.1% CAGR assumption.

Q: What are the major growth drivers? A: Need for rapid clinical decisions, decentralization of care, home testing, emergency/ambulatory workflows and improved connectivity.

Q: Which opportunities should suppliers prioritize? A: POC molecular testing, telehealth-enabled diagnostics, multiplex respiratory panels, home chronic-disease monitoring and emerging-market penetration.

Customization Options

Customization can include country-level sizing, procedure/test volumes, installed base, ASP benchmarking, hospital/lab account mapping, competitor benchmarking, product pipeline analysis, regulatory and reimbursement tracking, KOL mapping, distributor/channel assessment, and opportunity prioritization.

Need something this report does not cover?

Describe the decision you are facing. If a published study already answers it we will point you there; if not, we will scope the work and come back with timeline and cost.

CM-MD-0003 · CM-MD-P1-1003 · 180-220 pages · Published October 2026 · Cortex Meridian Medical Devices Analyst Team

Free Sample

Request a sample

Tell us where to send it. Samples include the table of contents, the methodology note and a representative section of the analysis.

Phone (Optional)
United Arab Emirates +971

This form is protected by reCAPTCHA. Google's Privacy Policy and Terms of Service apply.

We reply from insights@cortexmeridian.com within one working day. Your details are never shared.

Before You Buy

Enquire before buying

Ask before you commit. An analyst who knows the study answers — and if it does not cover what you need, they will say so rather than sell it to you.

Phone (Optional)
United Arab Emirates +971
What would you like to know?

This form is protected by reCAPTCHA. Google's Privacy Policy and Terms of Service apply.

We reply from insights@cortexmeridian.com within one working day. Sending this does not commit you to a purchase, and your details are never shared.

Custom Research

Customise your request

Tell us what you are trying to decide and we will come back with the scope, timeline and cost — or point you to a published report if one already answers it.

Phone (Optional)
United Arab Emirates +971
ReportPoint-of-Care Diagnostics Market

This form is protected by reCAPTCHA. Google's Privacy Policy and Terms of Service apply.

We reply from insights@cortexmeridian.com within one working day. Your details are never shared.

No obligation

Schedule a consultation

Thirty minutes with a senior analyst. If published research already answers your question, we will point you to it and say so.

Phone (Optional)
United Arab Emirates +971

This form is protected by reCAPTCHA. Google's Privacy Policy and Terms of Service apply.

We reply from insights@cortexmeridian.com within one working day. Your details are never shared.